The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study.
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Incyte; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); JPH Clinical Development (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masayuki Furukawa
Research Funding - Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD Oncology (Inst); Ono Yakuhin (Inst); Taiho Pharmaceutical (Inst)
 
Chigusa Morizane
Honoraria - Eisai; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - MSD K.K.; SERVIER; Yakult Honsha
Research Funding - AstraZeneca (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); Hitachi (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Tetsuo Takehara
Speakers' Bureau - Abbvie; ASKA Pharmaceutical Co., Ltd.; Bristol-Myers Squibb Company; Chugai Pharma; EA Pharma; Eisai; Gilead Sciences; Janssen; Kowa; Lilly Japan; Nihon Pharma; Nippon Kayaku; Otsuka; Rohto Pharmaceutical; Shionogi; Sumitomo Pharma Co., Ltd.; Taisho Pharmaceutical Holdings; Takeda; Zeria Pharmaceutical
Research Funding - Abbvie; ASKA Pharmaceutical Co., Ltd.; Bristol-Myers Squibb Company (Inst); Chugai Pharma; DAIICHI SANKYO Co., Ltd.; EA Pharma; Eisai; Gilead Sciences; GlaxoSmithKline (Inst); J-Pharma (Inst); Janssen (Inst); Kowa; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD K.K.; Nippon Kayaku; Novo Nordisk (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Otsuka; Rohto Pharmaceutical (Inst); Sumitomo Pharma Co., Ltd.; Takeda; Zeon Medical; Zeria Pharmaceutical
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Akiko Todaka
Honoraria - Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Naohiro Okano
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - GlaxoSmithKline
 
Kazuo Hara
No Relationships to Disclose
 
Yousuke Nakai
Honoraria - AstraZeneca; Daiichi Sankyo; Kyorin; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
 
Kazuyoshi Ohkawa
Speakers' Bureau - Astellas Pharma; Century Medical; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; Hisamitsu Pharmaceutical; Incyte; Takeda
Research Funding - Sumitomo Chemical (Inst); Towa (Inst)
 
Takashi Sasaki
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Taiho Pharmaceutical; Yakult Honsha
 
Kazuya Sugimori
No Relationships to Disclose
 
Naoyuki Yokoyama
No Relationships to Disclose
 
Kouji Yamamoto
Honoraria - Chugai Pharma; CMIC Co., Ltd.; J-Pharma; Sysmex; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Kyowa Kirin International (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)